Why the study?
Does the novel factor Xa inhibitor SR90107a/ORG31540 improve thrombus mass in patients with symptomatic proximal deep vein thrombosis compared to dalteparin?
Population
453 patients with symptomatic proximal deep vein thrombosis
Comparison
SR90107a/ORG31540 at 5, 7.5, or 10 mg once daily vs Dalteparin 100 IU/kg twice daily
Design
RCT, randomized-parallel-group, outcomes interpreted with the observer unaware…
Follow-up
3 months
Loading...
SR90107a/ORG31540 yields comparable thrombus resolution to dalteparin across doses; confirms a synthetic factor Xa inhibitor as alternative for acute proximal DVT.
Does the novel factor Xa inhibitor SR90107a/ORG31540 improve thrombus mass in patients with symptomatic proximal deep vein thrombosis compared to dalteparin?
The novel synthetic factor Xa inhibitor SR90107a/ORG31540 demonstrated comparable efficacy and safety to dalteparin for the initial treatment of proximal deep vein thrombosis across a range of doses.
A 2000 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: